Drugs in ATC Class C05B

Up to Top Level ATC Classes

Up to C - Cardiovascular system

Up to C05 - VASOPROTECTIVES

Subclasses in ATC: C05B - ANTIVARICOSE THERAPY

C05BA - Heparins or heparinoids for topical use

C05BB - Sclerosing agents for local injection

C05B Market Analysis and Financial Projection

The global market for antivaricose therapy (ATC Class C05B) is experiencing robust growth, driven by technological innovations, demographic shifts, and evolving treatment paradigms. Below is an in-depth analysis of the market dynamics and patent landscape shaping this sector.

---

Market Overview

• The varicose vein treatment market was valued at $1.38 billion in 2023, with projections reaching $2.42 billion by 2032 at a 6.4% CAGR[1][13]. Alternative forecasts suggest a slightly higher 6.8% CAGR, pushing the market to $1.48 billion by 2033[13].
• Compression therapy, a key adjunct to C05B treatments, is forecast to grow from $4.58 billion in 2023 to $8.40 billion by 2033 (6.25% CAGR)[6].
• Minimally invasive procedures dominate, with endovenous laser systems holding 52.47% market share in 2022[13].

---

Growth Drivers

1. Demographic Factors:

   • Aging populations and rising obesity rates amplify venous disorders, affecting 25–30% of adults globally[6][10].
   • Women are disproportionately impacted due to hormonal changes during pregnancy and menopause[3][10].

2. Technological Advancements:

   • Endovenous laser therapy (EVLT) and radiofrequency ablation (RFA) reduce recovery time and complications compared to surgery[8][14].
   • Innovations like ultrasound-guided procedures and 3D imaging enhance precision[8][10].

3. Expanding Treatment Applications:

   • Polidocanol, traditionally a sclerosing agent, now shows immunomodulatory effects, improving conditions like psoriasis and rheumatoid arthritis[2].
   • Heparin formulations (e.g., topical gels) are used for edema and thromboprophylaxis[5][12].

4. Healthcare Infrastructure:

   • Growth in ambulatory surgical centers and favorable reimbursement policies accelerate adoption[6][14].

---

Patent Landscape

Key Innovations

Patent/Technology	Description	Impact
Polidocanol Immunomodulation (Patent No. 102018000006109)	Buffered polidocanol reduces venous diameter, boosts VEGF levels, and modulates inflammation[2].	Expands use beyond sclerotherapy to autoimmune and anti-aging therapies[2].
Non-Invasive Valve Device (WO1999044560A1)	External pressure device mimics venous valves, restoring blood flow without surgery[4].	Reduces reliance on invasive procedures and compression stockings[4].
Anti-C5 Antibody Regimens (WO2021019036A1)	Subcutaneous Crovalimab dosing for complement-related diseases (e.g., PNH)[7].	Potential crossover into venous disorders requiring immunomodulation[7].

Trends

• Shift to Combination Therapies: Integration of sclerosing agents (e.g., polidocanol) with compression therapy[6][12].
• Biologic Therapies: Emerging patents targeting VEGF and inflammation pathways[2][7].
• Device-Pharma Hybrids: BTG plc’s Varithena (polidocanol foam) combines drug delivery with medical devices[14].

---

Regional Insights

• North America: Leads with $2.7 billion revenue in 2023 due to advanced healthcare infrastructure and high awareness[10][14].
• Asia-Pacific: Fastest-growing region (6.25% CAGR) driven by medical tourism, e-commerce adoption, and rising chronic disease burdens[6][10].
• Europe: Strong R&D activity, exemplified by Biolitec’s LEONARDO mini laser system and polidocanol patents[2][14].

---

Challenges and Opportunities

Challenges	Opportunities
Regulatory hurdles for biologics[7]	Personalized medicine via AI/3D imaging[8]
Generic competition[5]	Expansion into emerging markets[6][10]
High treatment costs	E-commerce platforms for compression gear[6]

---

Future Outlook

• 2025–2035: The market will likely see 5.5% CAGR for varicose veins treatments, fueled by AI integration and hybrid therapies[3][8].
• Emerging Trends:
  • Thermal management and vertical GaN devices for precise energy delivery[9].
  • Patent disputes (e.g., EPC vs. Innoscience) may spur collaborations in GaN electronics for medical devices[9].

Highlight: "The low concentrations [of polidocanol] showed immunomodulatory effects, translating into marked attenuation of inflammatory cascades." [2]

---

In summary, the C05B antivaricose therapy market is poised for sustained growth, driven by minimally invasive innovations, biologic advancements, and strategic regional expansions. Patent activity reflects a shift toward multifunctional therapies and device-pharma hybrids, positioning the sector for dynamic evolution.

References

1. https://www.zionmarketresearch.com/report/varicose-vein-treatment-market
2. https://www.ippocrateparma.it/en/who-we-are/patent/
3. https://www.biospace.com/press-releases/varicose-veins-market-size-predicted-to-grow-at-a-steady-cagr-of-5-5-during-2025-2035-impelled-by-rising-prevalence-of-venous-disorders
4. https://patents.google.com/patent/WO1999044560A1/en
5. https://go.drugbank.com/drugs/DB01109
6. https://www.precedenceresearch.com/compression-therapy-market
7. https://patents.google.com/patent/WO2021019036A1/en
8. https://www.openpr.com/news/3877539/shaping-the-varicose-veins-treatment-market-in-2025-increasing
9. https://www.knowmade.com/patent-analytics-services/patent-report/gan-electronics-patent-landscape-analysis-2023/
10. https://www.gminsights.com/industry-analysis/chronic-venous-occlusions-treatment-market
11. https://www.frontiersin.org/journals/research-metrics-and-analytics/articles/10.3389/frma.2023.978249/full
12. https://atcddd.fhi.no/atc_ddd_index/?code=C05B&showdescription=yes
13. https://www.futuremarketinsights.com/reports/varicose-veins-treatment-devices-market
14. https://www.industryarc.com/Report/17006/varicose-vein-treatment-market.html